Here's Why We Think Green Cross Health (NZSE:GXH) Is Well Worth Watching




  • In Business
  • 2022-11-26 20:31:26Z
  • By Simply Wall St.
 

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But as Peter Lynch said in One Up On Wall Street, 'Long shots almost never pay off.' A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.

In contrast to all that, many investors prefer to focus on companies like Green Cross Health (NZSE:GXH), which has not only revenues, but also profits. Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Green Cross Health with the means to add long-term value to shareholders.

View our latest analysis for Green Cross Health

How Quickly Is Green Cross Health Increasing Earnings Per Share?

If a company can keep growing earnings per share (EPS) long enough, its share price should eventually follow. So it makes sense that experienced investors pay close attention to company EPS when undertaking investment research. We can see that in the last three years Green Cross Health grew its EPS by 15% per year. That growth rate is fairly good, assuming the company can keep it up.

Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. EBIT margins for Green Cross Health remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 18% to NZ$670m. That's progress.

The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.

Since Green Cross Health is no giant, with a market capitalisation of NZ$178m, you should definitely check its cash and debt before getting too excited about its prospects.

Are Green Cross Health Insiders Aligned With All Shareholders?

Theory would suggest that it's an encouraging sign to see high insider ownership of a company, since it ties company performance directly to the financial success of its management. So we're pleased to report that Green Cross Health insiders own a meaningful share of the business. Owning 37% of the company, insiders have plenty riding on the performance of the the share price. Shareholders and speculators should be reassured by this kind of alignment, as it suggests the business will be run for the benefit of shareholders. In terms of absolute value, insiders have NZ$66m invested in the business, at the current share price. That should be more than enough to keep them focussed on creating shareholder value!

Is Green Cross Health Worth Keeping An Eye On?

One positive for Green Cross Health is that it is growing EPS. That's nice to see. For those who are looking for a little more than this, the high level of insider ownership enhances our enthusiasm for this growth. That combination is very appealing. So yes, we do think the stock is worth keeping an eye on. What about risks? Every company has them, and we've spotted 1 warning sign for Green Cross Health you should know about.

Although Green Cross Health certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see insider buying, then this free list of growing companies that insiders are buying, could be exactly what you're looking for.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You'll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here

COMMENTS

More Related News

The past year for Oxford Biomedica (LON:OXB) investors has not been profitable
The past year for Oxford Biomedica (LON:OXB) investors has not been profitable

Oxford Biomedica plc ( LON:OXB ) shareholders should be happy to see the share price up 26% in the last quarter. But...

DBS Group Holdings (SGX:D05) Ticks All The Boxes When It Comes To Earnings Growth
DBS Group Holdings (SGX:D05) Ticks All The Boxes When It Comes To Earnings Growth

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

TAT Technologies (NASDAQ:TATT) shareholders have endured a 41% loss from investing in the stock five years ago
TAT Technologies (NASDAQ:TATT) shareholders have endured a 41% loss from investing in the stock five years ago

TAT Technologies Ltd. ( NASDAQ:TATT ) shareholders should be happy to see the share price up 12% in the last month. But...

Investing in Intapp (NASDAQ:INTA) a year ago would have delivered you a 53% gain
Investing in Intapp (NASDAQ:INTA) a year ago would have delivered you a 53% gain

The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking...

Investors in Bicycle Therapeutics (NASDAQ:BCYC) have made a impressive return of 157% over the past three years
Investors in Bicycle Therapeutics (NASDAQ:BCYC) have made a impressive return of 157% over the past three years

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business